Business context and reporting period
This is Bioblast Pharma Ltd.’s Form 20-F annual report for the fiscal year ended December 31, 2017, filed April 23, 2018—not a quarterly report. The request names Enlivex Ltd.; the filing identifies the registrant as Bioblast Pharma Ltd. and its ticker as ORPN. Verify the company and filing identity before relying on this summary.
Bioblast was a clinical-stage biotechnology company developing intravenous trehalose for rare diseases, principally OPMD and SCA3. In 2017 it shifted away from active product development and engaged JSB-Partners to pursue potential product partnerships, licensing, a merger or sale, or a reverse IPO. It cut costs, terminated most employees, and vacated its offices. As of April 20, 2018, it reported two employees.
Financial performance and position
Amounts below are in U.S. dollars; financial-statement amounts are in thousands except per-share data. The filing reports annual, not standalone fourth-quarter, results.
| Metric | 2017 | 2016 | Change / context |
|---|---|---|---|
| Revenue | None | None | No product revenue; no commercial products |
| Research and development expense | $2,517 | $8,881 | Down 72% |
| Pre-commercialization expense | $479 | $1,085 | Down 56% |
| General and administrative expense | $2,959 | $5,900 | Down 50% |
| Total operating expenses / operating loss | $5,955 | $15,866 | Expense reduction reflected curtailed activity and downsizing |
| Net loss | $5,945 | $16,022 | Loss narrowed by about 63% |
| Basic and diluted loss per share | $1.79 | $5.03 | Loss per share |
| Cash used in operating activities | $6,352 | $15,486 | Cash burn declined with reduced clinical and corporate spending |
| Cash and cash equivalents | $3,526 | $6,871 | 2016 also included $3,007 in short-term bank deposits |
| Total assets | $3,622 | $10,630 | |
| Total liabilities | $460 | $1,931 | No long-term liabilities reported |
| Shareholders’ equity | $3,162 | $8,699 |
There is no meaningful operating margin because the company had no revenue. At year-end, current assets were $3.622 million and current liabilities were $460,000; the filing reported no outstanding borrowings. Cash and cash equivalents plus short-term deposits fell from approximately $9.9 million to $3.5 million.
Material changes, outlook, risks and unusual items
- Management estimated that year-end cash would fund activities at least through the third quarter of 2018; elsewhere the filing describes funding through at least the end of 2018. Additional funding would be needed to resume clinical development. The independent auditor’s report and the financial-statement notes state that substantial doubt exists about the company’s ability to continue as a going concern.
- Clinical development was effectively on hold while the company pursued strategic alternatives. The contemplated OPMD Phase 2b trial—planned for 48 patients over 24 weeks—was conditional on regulatory and funding availability; the filing does not report that it had begun.
- Management reported encouraging but preliminary Phase 2a observations in OPMD and SCA3. The OPMD study was open-label and not powered for efficacy; the SCA3 study was also open-label and small. These results do not establish efficacy or predict later-trial outcomes.
- Unusual cost and restructuring items included a $52,000 write-off of property and equipment after lease termination and a $16,000 early-termination lease penalty. The company paid JSB-Partners $160,000 in 2017 and agreed to a transaction-based fee if a deal resulted.
- Key risks include failure to complete a transaction or raise capital, continued Nasdaq listing, clinical and regulatory uncertainty, dependence on single-source suppliers and manufacturers, and potential shareholder dilution. The company regained Nasdaq’s $1 minimum bid-price compliance after a 1-for-5 reverse split, but disclosed continuing delisting risk.
- The filing reports no material litigation or off-balance-sheet arrangements. Management concluded disclosure controls and internal control over financial reporting were effective at December 31, 2017; the auditor did not provide an internal-control attestation.
Investor verification priorities
- Confirm that Bioblast Pharma Ltd.’s 2017 Form 20-F—not an Enlivex filing—is the intended document, and distinguish annual figures from any fourth-quarter results.
- Check subsequent cash balances, actual cash runway, financing availability, and whether a transaction or other funding was completed.
- Verify the status and terms of any partnership, licensing, merger, sale, or reverse-IPO process, including potential fees, dilution, and shareholder approvals.
- Confirm whether trehalose development resumed and review any later trial registrations, regulatory decisions, and complete clinical data.
- Review the going-concern disclosure, subsequent events, Nasdaq listing status, and the effects of the reverse split and any later share issuance.